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The implications of HIV infection 
on the management of valvular 
heart disease in Southern Africa
This review addresses the management of valvular heart disease 
in HIV patients, and the issues surrounding diagnosis and treatment 
in the South African context. 
CARDIAC DISEASE IN HIV                                           
The nature and pattern of cardiovascular involvement in HIV/
Aids have been extensively investigated(2,3) and reviewed in 
western literature.(4,5,6) Cardiac involvement in patients with HIV/
Aids (Table I) is relatively common and associated with increased 
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HIV AND VALVULAR 
HEART DISEASE IN 
SOUTHERN AFRICA
INTRODUCTION                                                             
South Africa has one of the most rapidly growing human immune 
defi ciency virus (HIV) epidemics in the world with an estimated 
5.7 million HIV positive people.(1) Of the 6 800 new HIV infec-
tions that occurred per day in the world in 2007, more than 
two out of three adults (68%) and nearly 90% of children infected 
with HIV live in Sub-Saharan Africa.(1) Although 18% of these 
infections occurred in young adults (15-49 years) little attention 
has been paid to the comor bidity associated with HIV seroposi-
tivity. In fact, except for tuberculosis and opportunistic infections, 
there are no specifi c guidelines that are available for the manage-
ment of different comorbid diseases in these patients that 
demand attention in their own right. 
Most decision-making regarding management in HIV patients 
is infl uenced by immune status, often taking the CD4 count 
into consideration. However,  it is not infrequent that arbitrary 
decision-making approaches are adopted, and intervention/
surgery turned down on the basis of HIV seropositivity alone. 
There is very limited information on the disease profi le 
and treatment approaches in HIV patients with valvular 
heart disease (VHD) in developing countries. HIV infection 
impacts on patients with VHD in three settings: HIV/
Aids as a comorbid disease in patients with underlying 
valve disease, infective endocarditis secondary to immuno-
suppression, and non-infective valve involvement from 
myocardial failure or from marantic endocarditis. 
The clinical presentation of infective endocarditis does not 
differ between HIV and non-HIV patients, with the exception 
that intravenous drug abuse is a common cause in specifi c 
populations. While peri-operative mortality and morbidity 
is high in acute infective endocarditis, surgical interventions 
do not increase the postoperative risk for complications or 
death and should therefore not be withheld. There is also 
little evidence to suggest that HIV or antiretroviral drugs 
increase the rate of cardiac-related pregnancy complications 
or that pregnancy may alter the course of HIV infection.
Since antiretroviral therapy has been associated with 
considerable improvement in clinical status prior to surgery, 
as well as in long term outcomes, all patients with valve 
disease in whom intervention is likely should undergo HIV 
testing and staging so that highly active antiretroviral 
treatment (HAART) may be instituted timeously. 
Conclusion:  The high prevalence of HIV in our population 
makes consideration of this comorbidity an essential facet in 
the routine evaluation and management of patients with 
VHD.  There is solid evidence that these patients do no 
worse than non-HIV patients undergoing medical treatment 
or percutaneous/surgical intervention – open-heart surgery 
may be offered safely to patients with HIV if proper pre-




















morbidity and mortality. The spectrum ranges from pericardial 
disease with effusion, to myocardial disease, as well as involve-
ment of the valve endocardium. With the advent of highly active 
antiretroviral therapy (HAART), coronary artery disease and 
dyslipidaemia, drug-related cardiotoxicity and cardiac autonomic 
dysfunction have begun to emerge and are becoming increasingly 
prevalent.(7)
MYOCARDIAL INVOLVEMENT IN HIV                       
Little change in cardiac function has been documented in ambula-
tory HIV positive patients.(8,9)  Diastolic abnormalities have been 
reported in patients without clinical evidence of cardiac disease.(10) 
Advanced systolic dysfunction is more common in the patients 
classifi ed as having Aids,(8) but there has been a decline in 
cardiomyopathy with the advent of HAART in the developed 
countries.(11)  In contrast heart involvement in developing countries 
is dominated by pericardial tuberculosis, often accompanied by 
impairment of left ventricular function due to associated myo-
carditis.(12,13,14)   
In prospective cross sectional studies in Africa which have 
included patients with Aids, the prevalence of dilated cardio-
myopathy has been reported to vary from 15% to 35%(15,16,17) 
compared to the 15% overall reported in a western series by 
Currie.(18) A study from Cameroon evaluated cardiac involve-
ment in 75 African patients according to the clinical stage of the 
disease and the immunological status of the patients.(15)  This study 
found that dilated cardiomyopathy occurred in 7/30 (23.33%) 
of Aids patients, 1/24 (4.17%) HIV positive non-Aids patient, but 
in none of the HIV negative subjects. In this study dilated cardio-
myopathy occurred in six (31.58%) of the patients with a CD4 
cell count  100 cells/microlitre and in two (6.06%) with CD4 
counts > 100 cells/microlitre (chi2 = 4.02, p = 0.03).  This associa-
tion of cardiomyopathy with more advanced immunosuppres-
sion and lower CD4 counts is consistent with international 
experience.(18) Global left ventricular dysfunction is typically found 
in the late stages of HIV infection. The clinical picture of dilated 
cardiomyopathy is strongly associated with CD4 counts < 100 cells/
microlitre.
 
ACUTE INFECTION AND LV DYSFUNCTION                     
The cause of heart muscle disease in patients with HIV infection 
is not clear. Autopsy studies document a high prevalence of 
myocarditis (46%), but in over 80% of cases no specifi c aetiology 
has been found.  Many cases seem to be related to a lympho-
cytic myocarditis directly related to the HIV infection, while 
opportunistic infection accounts for the remaining 20% (examples 
being cytomegalovirus/toxoplasma gondii infection).(18) Other 
potential pathogenic factors include nutritional defi ciencies, the 
cardiotoxic effects of antiretroviral drugs and other opportunistic 
infections.
Regardless of its aetiology the presence of impaired left ventri-
cular function in these subjects is an independent adverse 
prognostic factor ; it is associated with very low CD4 counts and 
with reduced survival compared to those with normal hearts, 18 
which poses serious challenges in the medical and surgical treat-
ment of valve-related disease. 
TABLE 1:  Cardiac disease associated with HIV and Aids 
Pericarditis and Pericardial effusion (TB)






Increased risk of coronary artery disease
Abnormal lipid metabolism and lipodystrophy syndrome






VALVE INVOLVEMENT IN HIV                                    
To date most reports on valvular heart disease (VHD) in HIV 
infected patients have focused on infective endocarditis (IE) in 
drug addicts.(19,20,21,22,23) If, as Levy suggested, the risk of deve-
loping IE in HIV positive patients is related to the degree of 
immune paresis(3) then one would expect low CD4 counts to 
increase the risk of bacteremia, and subsequent seeding on the 
valve tissue would predispose to infective endocarditis, parti-
cularly in subjects with a predisposing valve/cardiac lesion.(3) 
Bacteremia is indeed common in the HIV positive patients, due 
to the numerous immunologic defects present in this disease.(24) 
IE is reported to be common in advanced HIV patients, and 
mortality increases with a decreasing CD4 count.(19,25)  The rise 
in staphylococcal infections, and the immune paresis associated 
with Aids pose diagnostic challenges, and they also have import-
ant implications for management in these patients.(25)  Furthermore 
infection may be caused by unusual organisms, such as bartonella, 
salmonella and listeria.(26,27)
Although infective endocarditis is the most common cardiac 
complication of HIV/Aids in the Western world,(20) the clinical 
outcome in these patients appears to depend more on the valve 
affected and the virulence of the organism rather than the HIV 
serostatus.(20)  
In a large series of 263 cases of defi nite IE (Dukes criteria), 
including a 100 cases in HIV positive patients, over a 13- year period 
in intravenous drug users between 1986 and 1999 in the pre-
HAART era  De Rosa  found no major differences in outcome 
between HIV negative and HIV positive patients.(21) In another 
large series of 493 cases of native valve endocarditis (220 cases 
in intravenous drug users) diagnosed from 1985 to 1999 Martin-
Davila analysed 13 variables, including HIV serostatus and CD4 
cell count < 200 cells/microlitre, and showed that the main 
prognostic factors of in-hospital mortality in right-sided IE were 
large vegetations > 2 cm and fungal etiology.(28)  As with cardio-
myopathy it is reported that IE rates have decreased in the 
current HAART era from 20.5 to 6.6 per 1 000-person-years(29) 
accompanied by an appearance of noninfective valvular disease 
(marantic and rheumatic causes NIVD) and coronary artery 
disease (CAD) in HIV patients.(5,30) In multivariate regression an 
increased risk of IE occurred in intravenous drug users (odds 
ratio 8.71), those with CD4 counts <50 cells/microlitre, and 
those with HIV-1 RNA >100 000 copies/ml.(29) The most 
common aetiologic organism was Staphylococcus aureus (40 
(69%) of these 11 (28%) were methicillin resistant). Within 
1-year, 16% had IE recurrence and 52% died. Also a new pattern 
of IE in IVDA is emerging, characterised by more frequent 
left heart involvement (61.5%), a severe clinical course, and a 
need for surgery in the active phase.(22)
HIV ASSOCIATED INFECTIVE ENDOCARDITIS         
IN  AFRICA
There are few reports of infective endocarditis in HIV/Aids 
from developing countries.(31,32) Despite the high prevalence of 
rheumatic heart disease it is distinctly uncommon in our environ-
ment, probably due to the low prevalence of mainline drug 
addiction.  A 3-year survey of IE at our centre found that 
the clinical profi le in the HIV positive patient was similar to the 
HIV negative patient, and was characterised by fever, clubbing, 
murmurs and severe valve regurgitation with similar responses 
to therapy.(32)  The CD4 counts in 4/17 HIV infected  patients who 
demised  were 139, 135, 149 and 249 cells/microlitre3.  This is in 
contrast to the fi ndings of the Emory group who suggested 
that there was no correlation between the mortality and the 
degree of immunosuppression.(24,33)  The most common under-
lying predisposing abnormality in our series is rheumatic heart 
disease. Although S.aureus and S.viridans are the common 
infecting organisms,(20) a high rate of culture negativity has been 
reported(31,32) probably related to prior antibiotic therapy, and 
in the absence of microbiological indices the sensitivity of the 
modifi ed Duke criteria is diminished.(34) The lack of specifi city in 
echocardiographic criteria becomes apparent when diagnosing 
IE in the HIV population, as these patients often have elevated 
ESR and CRP levels due to anaemia or non-valvular infection. 
Furthermore it is also being increasingly recognised that non-
bacterial thrombotic endocarditis (NBTE) may be the cause when 
blood culture is negative.(35) NBTE is characterised by the 
presence of friable vegetations on cardiac valves, which consist 



















of fi brin and platelet aggregates and is being increasingly 
recognised as a potentially life-threatening source of thrombo-
embolism. NBTE occurs in 3 to 5% of Aids patients, mostly in 
patients with extreme wasting. It is often diffi cult to diagnose 
and one has to rely on strong clinical suspicion. Even with an 
established diagnosis, treatment of NBTE is diffi cult. In the non-
HIV patients anticoagulation has been instituted  although there 
are no prospective randomised studies to support this strategy. 
There are also no guidelines for surgical intervention in patients 
with NBTE. Systemic embolisation from marantic endocarditis in 
the Aids patient is a rare cause of death in the HAART era. 
In haemodynamically stable patients surgical intervention is 
generally not recommended unless the patient develops severe 
valve damage with resultant heart failure. 
EFFECTS OF IMMUNE SUPPRESSION ON                   
CLINICAL MANIFESTATIONS AND OUTCOME
It is not clear to what extent HIV may alter the clinical picture 
of underlying valvular heart disease, or worsen the progression of 
the disease and the haemodynamic changes such as pulmonary 
hypertension. In HIV patients with IE abscess formation with 
paravalvular extension has been reported, which could be related 
to the advanced stage of immune defi ciency, but the numbers are 
too few to draw fi rm conclusions.(32,36)  In Nel’s series four out of 
seventeen HIV positive patients with infective endocarditis had 
advanced immunodefi ciency with a mean CD4 count <100 cells/
microlitre. When the HIV positive patients were stratifi ed into 
2 groups: CD4 counts <200 cells/microlitre; and >200/mm3, 
Nel did not fi nd any differences in the clinical features, nor 
were there any differences in the infecting organism between 
the groups. There were four known deaths amongst the HIV 
positive patients (23.6%), and fourteen deaths amongst the HIV 
negative patients (23.3%) (p = ns). 
Signifi cant morbidity was present in these patients, such as 
anaemia, concomitant TB and dialysis-requiring renal failure.(26) 
Nosocomial infection leading to prosthetic valve and catheter-
related endocarditis poses serious challenges in management 
because of the emergence of antibiotic resistance among causative 
organisms.(29) 
IMPACT OF HIV SEROSTATUS ON UNDERLYING    
VALVULAR HEART DISEASE:
Information from a cardiac disease in pregnancy cohort
Women of reproductive age are the fastest growing population 
with HIV, and in developing countries rheumatic heart disease 
(RHD) is a major cause of maternal morbidity(37) and mortality.(38,39) 
Recent reviews have not focused on the impact of HIV serostatus 
in these patients.(40,41)  Two studies have shown that  HIV serostatus 
does not modify the treatment effects in patients with cardiac 
disease during pregnancy.(42,43) In a one year review of 95 
patients with cardiac disease in pregnancy during 2003.(43) At 
our institution (Inkosi Albert Luthuli Central Hospital, Durban) 
Nqayana et al. found 31 (33%) patients to be HIV positive; 46 
tested negative and  the remaining 18 declined testing.  Rheumatic 
heart disease was the commonest aetiology (81%).  There were 
22 patients with isolated mitral stenosis, and 11 were New York 
Heart Association (NYHA) III-IV. Four patients had undergone 
balloon mitral valvuloplasty (BMV) prior to pregnancy. Eight 
patients (4 HIV positive) required intervention, and percutaneous 
valvuloplasty was accomplished successfully during pregnancy. 
Cardiac complications were mainly related to rhythm disturbances 
and heart failure while bleeding from over-anticoagulation 
accounted for the majority of the non-cardiac complications 
(Table 3).  Maternal morbidity and adverse fetal outcomes were 
associated with late presentation and problems with anticoagula-
tion, not with HIV serostatus. 
Outcome measures were similar in HIV-infected and non-infected 
groups (Table 5).  The mean CD4 count was 463 cells/microlitre 
(range 79-1419). The ejection fraction was normal in all patients 
except for three with cardiomyopathy (Table 2). Of note Nqayana 
found that HIV infected women did not have a higher wound 
infection rate, puerperal sepsis rate, nor was there a higher neo-
natal infection rate compared to non-HIV infected women. Nor 
did there appear to be any difference in outcome in the 3 
women who had advanced disease with low CD4 counts (< 200 
cells/microlitre). The provision of antiretrovirals for maternal 
health had just begun and the standard of care at the time of this 
study was the provision of single dose of nevirapine given to the 
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mother at the time of birth, and to the baby within 24 hours of 
delivery, for the prevention of mother to child HIV transmission. 
The limited evidence to date suggests that HIV infection or 
antiretroviral drugs do not increase the rate of cardiac-related 
pregnancy complications nor does pregnancy alter the course of 
HIV infection.(44) 
IMPACT OF HIV SEROSTATUS AND                           
COMORBIDITY IN PATIENTS UNDERGOING          
CARDIAC VALVE SURGERY 
To date, most valve surgery has been in patients with infective 
endocarditis related to intravenous drug use (Table 3).  Recently(45) 
Blyth et al. reviewed the records of 49 HIV infected non-IVDA 
patients (65% female), undergoing surgery over a nine-year 
period (1995-2003) at our centre. Of these 45 patients had 
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TABLE 3:  Cardiac surgery in HIV patients
*Not on HAART 
Studies, year Surgery No. of  Mean  Follow up Mean  Mortality  Comment
  country  patients  age (months) CD4  rate (%) 
    (surgeries)   (mean) pre-op      
Aris A, et al.  Mainly  40 30 4-72 (21) NA 20 early Aids not accelerated by
1993 Spain valve 85% IVDA    25 late CPB pathologies related to
        IVDA are causes of poor
              prognosis
Chong T, et al.  Valve 22 38 Up to 96 NA 45 late Low operative risk 
2003 US  73% IVDA     Poor late result associated
              with IVDA
Mestres CA, et al. Valve,  31(35) 35 2-171 278 22.6 early Increase in HIV pts 
2003 Spain coronary 19% IVDA    37.5 late requiring cardiac surgery 
        Decrease in acute IE 
        Late death not related to
              AIDS
Trachiotis GD,  Valve,  37 41 84 360 2.7 early Acceptable risk and
et al. 2004 coronary Few IVDA   >300   outcomes of cardiac surgery
US     selected  in selected HIV pts
Filsoufi  F, et al. Valve,  25 47 2-90 (44) 440  4 early Survival rate of 86% 
2006 US coronary 68% IVDA   12.5  late  at 3 years  
        Surgeons should not 
        hesitate to perform 
              major surgeries
Blyth DF, et al.* Mainly  49 (50) 33 2-70 (23) 685 6 early Surgery worthwhile 
 2006 South Africa valve No IVDA   >400  17.3 late in selected HIV pts 
      selected  No evidence that CPB 
        accelerated progression
        to Aids
TABLE 2:  Impact of HIV serostatus on pregnancy-associated heart disease
Modifi ed from Nqayana et al.(43)
MVR = mitral valve replacement.  NVD = normal vaginal delivery.  C/S = caesarean section
Parameter HIV (n=31) Non HIV (n=46)
Demographics  
Age (years) 18 - 39 15 - 45
Parity:  P0 12 19
Preterm 13 14
CD4 count <200 cells/microL 3 -
Balloon mitral valvuloplasty 4 4
Mitral valve replacement 1 -
Normal delivery 8 21























rheumatic valvular heart disease and 44 underwent cardio-
pulmonary bypass. Absence of clinical Aids and a CD4 count 
above 400 cells/microlitre, were the criteria used in selecting 
patients fulfi lling the usual criteria for surgery. All but one of 
the patients improved their functional class. Blyth concluded 
that surgery in HIV positive patients with CD4 counts >400 
cells/microlitre is likely to have a similar early outcome when 
compared with the HIV negative patients.(45) The outcome of 
surgery in patients with CD4 counts >400 cells/microlitre has 
been reported by Filsoufi (46) et al. who found a 86% 3-years 
survival in 25 patients undergoing cardiac surgery with CD4 
count of 51-1 050 (mean 440). Of these ten patients had CD4 
count < 400/microlitre. These fi ndings support our contention 
that surgeons should not hesitate to perform major surgical pro-
cedures in patients with AIDS or HIV infection per se, whenever 
they are indicated.
The issue of the timing of surgery in these patients arises when 
there is comorbid infection, particularly tuberculosis (TB). In 
South Africa it is estimated that >60% of TB patients have HIV 
co-infection. These patients are not infrequently referred for 
cardiac surgery, resulting in three confounding factors in thera-
peutic decision making i.e. initiation of anti-tuberculous therapy; 
timing of surgery; and the introduction of HAART. Drug inter-
actions between current HAART and anti-TB medications, as 
well as the immune reconstitution syndrome associated with 
initiation of HAART during TB treatment impose therapeutic 
challenges in the timing of treatment regimens and surgical 
intervention. The World Health Organisation’s (WHO) guide-
lines suggest that individuals with TB who have CD4 count 
<200 cells/microlitre should initiate HAART 2 to 8 weeks after 
starting TB treatment. In those with CD4 counts >200 cells/
microlitre HAART may be delayed until the initial intensive phase 
of TB treatment is complete. The timing of surgery in these 
patients will depend on urgency of the procedure. We have 
adopted a pragmatic approach with at least 2 weeks of anti-TB 
treatment before commencing HAART in those with CD4 
<200  who are in need of urgent surgery.
ISSUES RELATED TO CARDIAC SURGERY                      
(TABLE 4)
While it is recognised hospital mortality and pneumonia in HIV 
patients are higher than in uninfected cases in some series,(47,48) a 
retrospective analysis of patients undergoing general surgical 
procedures has shown that other operative outcomes were 
comparable for HIV infected and non-HIV infected patients.(48) 
Hospital mortality and complications in Blyth’s series were 
acceptably low (6% and 34.7% respectively) in a selected group of 
patients (CD4 count >400 cells/microlitre). Furthermore, except 
for undiagnosed preoperative infection (Tuberculosis1 and infective 
endocarditis1) he did not fi nd a higher wound infection rate in 
his patients; even the commonest early complication, pericardial 
TABLE 4:  Issues/challenges in the management of valve disease in HIV
Effects of immune suppression on clinical parameters : Hb, Platelets, albumin
Procedural risks
Blood sampling in HIV patients
TEE and use of sheath
Intervention/surgery
Bleeding complications  and anticoagulant therapy in HIV patients
Treatment response  and the effects of HIV on healing process
Emerging challenges 
Emergence of prosthetic valve and pacemaker-related endocarditis increase 
in antibiotic resistance among aetiologic organisms e.g. MRSA 
Increase in comorbid disease eg atherosclerosis, diabetes, dialysis-dependent 
renal failure, and drug abuse.(8)
Acute phase reactants (CRP and ESR often related to opportunistic 
infection, anaemia)
High prevalence of tuberculosis co-infection 
Simultaneous anti-tuberculous therapy and HAART
HAART in the peri-operative period
Issues in surgical management 
Prioritising against surgery in the HIV patient:
• Perception that surgery may accelerate the disease process  
• Perceived diminution in life expectancy 
• Quality of life vs life prolongation 
• Perceived contribution to society
Prioritising due to limited resources:
• Limited access to aftercare and antiretroviral therapy 
• Elective vs emergency care
• Delaying surgery in HIV positive patients
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effusion, was not related to bacterial infection. There is evidence 
that viral load of 30 000 copies per milliliter or more was asso-
ciated with increased complications (adjusted odds ratio, 2.95; 
P=.007), but a CD4 cell count less than 200 cells/microlitre was 
not associated with poorer outcomes following general surgery.(48)
PROGRESSION OF HIV INFECTION                            
Surgeons have been reluctant to operate in the belief that HIV-
related immune supppression would lead to poor surgical out-
comes and progression of disease. Blyth documented eight late 
deaths during follow-up of 43 cases, mostly from Aids Concern 
about the effects of bypass surgery, which have been allayed since 
it has now been shown that transient changes in the CD4 count 
during CPB is not associated with disease progression even when 
counts are low.(30,52,53) Also the recurrence of endocarditis in patients 
operated upon during the phase of active infection(54,55) has been 
found to be related to continuing intravenous drug abuse, and 
not due to the HIV status. Since the report by Mellors et al.(51) 
that viral load increases as Aids develops it has become established 
that viral load infl uences disease progression. Access to HAART 
is therefore critical in halting the progression to Aids and thereby 
late complications related to surgery .  
HAART in peri-operative period needs special attention. There 
are no specifi c guidelines for the initiation or the continuation of 
HAART in the peri-operative period. The timing of initiation 
depends on the urgency of surgery and clinical stage of the 
disease. The major issues to consider include the potential toxicity 
and the possibility of drug interactions associated with HAART, 
and the emergence of drug resistance should treatment be with-
held in the peri-operative period. Until further studies emerge, it is 
reasonable to continue HAART until operation and to administer 
medication post-operataively via nasogastric tube where possible.
ISSUES RELATED TO THE MANAGEMENT OF            
VALVE DISEASE (TABLE 5)
1. The role of echocardiography
The HIV patient with VHD presents unique challenges in 
management: in addition to the evaluation of disease severity 
the clinician is faced with the comorbidities arising from HIV 
serostatus. These include unsuspected abnormalities such as 
pericardial effusion, cardiomyopathy, pulmonary hypertension and 
infective endocarditis.  
A baseline echocardiographic evaluation at the time of HIV 
diagnosis with follow up scans every 2 years has been recom-
mended in subjects with VHD.(56) Lipshultz suggests that annual 
scans should be performed in symptomatic patients with referral 
to the cardiologist when cardiovascular abnormalities are 
detected. Clearly this recommendation is not appropriate in 
Southern Africa where rheumatic heart disease is endemic and 
there is a high rate of HIV infection. In our setting, while the 
indication for echocardiography should be symptom-driven, a 
full clinical evaluation of the symptomatology is mandatory 
before referral for echocardiography. 
TABLE 5:   Treatment principles in guiding percutaneous intervention/
surgery 
HIV is a chronic viral illness 
HIV infection should be regarded as a comorbidity factor like HbsAg
There is no scientifi c basis to:
• deny any intervention because of HIV infection; 
• discriminate in favour of non-HIV status; and 
• refuse to operate because of the risk of exposure.
Operative/interventional outcomes are similar for HIV infected and non-HIV 
infected patients 
Surgical treatment decisions should be the same as for non-HIV patient
Preoperative preparation in VHD 
Address comorbidity prior to surgery 
Exclude active pulmonary infection
Accurately determine ventricular function  
Determine the operative risk of anaesthesia and surgery
Peri-operative HAART therapy
Timing of surgery if CD4 count < 200/microL or “Aids defi ning illness 
(Kohli) 
6 weeks of HAART before urgent surgery



















2. The patient with acute dyspnoea
Many patients with HIV/Aids develop multiple opportunistic 
infections, and present with persistent or unexplained pulmonary 
symptoms, so that dyspnoea is often presumed to be of pul-
monary origin.  Echocardiography is an essential tool in the evalua-
tion of acute dyspnoea of hospitalised patient with HIV/Aids, 
especially when the shortness of breath is out of proportion to the 
pulmonary involvement. With the recognition that HIV cardio-
myopathy is often silent (see above), measurement of left ventri-
cular function should also be considered in the evaluation of 
unexplained dyspnoea in these patients, since the management 
in these instances is clearly different.  The detection of left ventri-
cular dysfunction calls for greater care in the management of 
comorbid infections since careful attention needs to be paid to 
fl uid and volume status in these patients. 
3.  Assessment of haemodynamic status and ventricular 
function
Of importance is a determination of the possible cause and 
severity of ventricular dysfunction when it is present. HIV related 
myocarditis consists of a cell-mediated injury of the myocytes and 
phenotypically appears identical to a subgroup of non-HIV
positive patients.(57) There is therefore little to be gained by 
performing myocardial biopsies in these patients prior to surgery. 
Furthermore, no prospective studies have evaluated the treat-
ment regimens in HIV associated cardiomyopathy. 
A decline in the incidence of HIV associated cardiomyopathy 
that has been documented in the post HAART era, suggests that 
the administration of HAART prevents opportunistic infection 
and could, in this way, reduce the incidence of pericardial effusion 
and myocardial involvement in these patients.(11) 
The development of severe pulmonary hypertension in the 
patient with valve disease may present a diagnostic dilemma.  It 
may be secondary to left-sided valve disease or it may be due to 
the HIV itself. HIV associated pulmonary hypertension is a well-
described entity with an incidence 1/200.(4) It presents with 
dyspnoea in young patients and in contrast to cardiomyopathy, 
shows no correlation with opportunistic infections or the CD4 
count. Plexogenic pulmonary arteriopathy is the most frequent 
pathologic fi nding and the prognosis is poor : half the patients 
are dead within a year. HIV associated pulmonary hypertension 
should only be diagnosed when other causes (thromboembolism, 
airway disease, valvular disease) have been excluded. 
It should be considered when the pulmonary hypertension is clearly 
out of proportion to the severity of valve involvement.
4. Increased atherosclerotic risk
The administration of HAART has been associated with an increase 
in the incidence of coronary heart disease in patients receiving 
protease inhibitors.(58) Recent reports also indicate that the 
metabolic changes associated with these drugs is accompanied 
by elevation in blood pressure in up to 74% of patients with 
metabolic syndrome. Careful screening is therefore essential in 
patients who are receiving HAART, especially in those with risk 
factors for coronary disease, as the atherogenic effect of treat-
ment may accelerate this risk.
5. Effects of  antiretroviral  therapy 
The improved survival of patients with HIV infection who 
have access to HAART has resulted in HIV becoming a chronic 
viral disease with a growing disease burden. The 5-year survival 
after surgery has improved from 48%(59) to 64.9% at one year(30) 
and in another study has been documented to be over 80% at 
3 years(46,52) in the post-HAART era.  The marked improvement 
in mortality with the use of ARVs reported by Palella(59) supports 
the contention that all patients should be offered surgery where 
it is indicated. 
6. Ethical issues
Although surgeons are prepared to operate on HIV carriers 
most are still are reluctant to operate on patients with Aids(54,60) 
despite the low risk of accidental skin injury.  Legal and ethical 
issues arise when patients are denied appropriate care without 
adequate grounds for such decisions being clear and documented. 
In the US(61) two surgeons are being sued by Ronald Flowers, 
a patient with HIV who was denied open-heart surgery at the 
George Washington University Hospital. The patient had suffered 
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two transient strokes secondary to a vegetative growth on his 
aortic valve. The surgeons felt that open-heart surgery on a 
HIV positive patient posed too great a risk for the surgical team, 
and the patient was transferred to another hospital where the 
surgery was successfully completed. This case draws attention to 
the ethics of withholding appropriate treatment when there is 
adequate literature to support surgery in HIV patients with 
valvular heart disease, taking the necessary precautions in those 
who test positive or who decline testing. Mestres noted that 
their unit is now more frequently referred HIV patients for 
surgery, possibly due to a greater acceptance of improved 
results.(30)  They now accept all referrals, regardless of Centre of 
Disease Control classifi cation.
CURRENT APPROACH AND SUGGESTED                  
GUIDELINES
There are several complexities in the clinical decision-making in 
the individual HIV infected patient, with a lack of data to 
support clear guidelines. Blyth’s retrospective review only included 
patients with CD4 counts >400. We do not know what the out-
come of the patients with lower CD4 counts (200-400) would 
have been. Horberg found that a viral load ≥ 30 000 copies/ml 
was associated with increased complications (adjusted OR 2.95; 
p=0.007).(48) Viral suppression to fewer than 30000 copies/ml 
reduced surgical complications. However, in this study Horberg 
pointed out that a CD4 count <200 was not associated with 
poorer outcomes. 
Although there was a higher rate of complications, Blyth found 
no increase in infections in his study. He therefore felt that 
patients with low counts could be placed on a waiting list 
while receiving HAART.  It has been well described that six 
months after starting HAART, the achieved CD4 cell count and 
viral load, but not values at baseline, are strongly associated 
with subsequent disease progression.  These fi ndings should inform 
our guidelines on selection for surgery and when to modify 
HAART in these patients.(65) 
 
We now perform routine voluntary HIV testing for all patients 
with VHD in whom intervention is imminent. As there are few 
operative guidelines(63) we base our elective management on 
immune status, taking the CD4 T-lymphocyte count into 
consideration.  When the CD4 T-cell count exceeds 400 cells/
microlitre, patients are managed according to standard protocols 
appropriate for sero-negative patients.  At this level Blyth reported 
that outcomes are similar to uninfected subjects, and there is no 
difference in the mortality rate.  Where the CD4 count is in the 
range 200-400 cells/microlitre our treatment approaches are still 
the same but our surgeons have adopted a conservative alternative 
to surgery in most instances, recently calling for the introduction of 
HAART and an estimation of the viral load.(64) Relying on CD4 
count and viral load as the only parameters for decision-making 
is not only too restrictive, but it also this does not take into 
account the Centers for Disease Control and Prevention (CDC) 
staging of infection, as was done by Filsoufi  et al. Furthermore 
the CD4 count has wide inter-test variability and shows poor 
correlation with clinical staging. Wasting used as a CDC indicator 
is also not reliable since it may be manifestation of cardiac 
cachexia associated with VHD. What seems to be appropriate is 
our setting is the patient’s general condition and associated 
comorbidity (Hb, albumin, renal function) and urgency of surgery. 
If the patient is in good general health, with a low viral load 
and without serious comorbidity, surgery is offered regardless of 
the CD4 count. 
Where the clinical staging and CD4 count is Aids defi ning (<200 
cells/microlitre), palliative treatment is administered unless surgery 
is deemed life-saving (e.g. stuck valve, atrial myxoma) and the 
patient is otherwise in good health. 
CONCLUSION                                                                 
In developing countries IE in HIV patients occurs mainly in 
patients with underlying RHD. The common infecting organisms 
are S. aureus and S. viridans. With increasing drug abuse the 
prevalence of endocarditis in HIV infected subjects in our 
environment will likely increase, posing further problems in 
diagnosis. Careful forward planning is essential in patients in 
whom interventional procedures are imminent.  In the absence of 



















guidelines (Table 6) may only be tentative, but are critical to 
appropriate management in our setting. A team involving the 
physician, cardiologist, virologist, cardio-thoracic surgeon and 
counsellor should be involved in the care of these patients, 
especially those requiring intervention/surgery. There are now 
several reports of successful treatment, including surgical out-
comes in HIV infected patients, even when the CD4 counts are 
low.  In addition to the fact that there is very little scientifi c basis 
for not offering surgical or percutaneous intervention to HIV 
infected patients there are serious moral and ethical issues 
that militate against such an approach.
TABLE 6:   Suggested guidelines in the evaluation of VHD HIV testing 
All patients under consideration for percutaneous intervention/surgery 
should undergo voluntary testing (HIV and HBsAg) after adequate pre-test 
counselling. 
Clinical and immunological staging should be applied using appropriate 
measures (CD4 count/ CD4/8 ratio/ CD 4 % and viral load)  
HAART should be initiated without delay where indicated
Evaluation of comorbidity
Estimation of acute phase reactants (ESR, CRP viral vs bacterial) to assess 
the activity of comorbid disease, including infection and carditis
Where endocarditis is suspected, blood cultures should be taken frequently, 
and where possible, prior to antibiotic therapy 
Aggressive treatment of coexistent infection (tuberculosis), and other 
comorbidities
Diagnostic evaluation 
Careful evaluation of disease severity including transthoracic echo (TTE) to: 
• evaluate the severity of valve dysfunction;
•  detect evidence of infective endocarditis (vegetations, paravalvular 
extension, prosthetic valve dehiscence); and
• document  ventricular dimensions and ventricular function. 
Transesophageal echo should be performed where TTE images are 
suboptimal,  with mechanical prosthetic valves, or if paravalvular infection is 
suspected:
•  adequate sterilisation of the transducer is a critical requirement since 
the risk of trauma during  passage of the scope is likely to be 
associated with bleeding in the presence of oesophageal candidiasis;
• using a protective sheath and gumguard; and
•  observe the usual precautions against needlestick injury - fully 
equipped crashcart on standby.
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